Background: Heart-lung transplantation (HLT) has provided hope to patients with end-stage lung disease and irreversible heart dysfunction. We reviewed the clinical outcomes of 10 patients who underwent heart-lung transplantation at Asan Medical Center. Methods: Between July 2010 and August 2014, a total of 11 patients underwent HLT at Asan Medical Center. After excluding one patient who underwent concomitant liver transplantation, 10 patients were enrolled in our study. We reviewed the demographics of the donors and the recipients' baseline information, survival rate, cause of death, and postoperative complications. All patients underwent follow-up, with a mean duration of 26.1±16.7 months. Results: Early death occurred in two patients (20%) due to septic shock. Late death occurred in three patients (38%) due to bronchiolitis obliterans (n=2) and septic shock (n=1), although these patients survived for 22, 28, and 42 months, respectively. The actuarial survival rates at one year, two years, and three years after HLT were 80%, 67%, and 53%, respectively. Conclusion: HLT is a procedure that is rarely performed in Korea, even in medical centers with large heart and lung transplant programs. In order to achieve acceptable clinical outcomes, it is critical to carefully choose the donor and the recipient and to be certain that all aspects of the transplant procedure are planned in advance with the greatest care.
INTRODUCTION
Since the first case of heart-lung transplantation (HLT) was conducted at Stanford University in 1981 [1] , 3,755 adult HLTs (including re-transplantation) have been performed worldwide as of June 2013 [2] . Initially, the majority of HLTs were performed for pulmonary vascular disease and cystic fibrosis, which had previously been treated with lung transplantation alone. Recently, the major indications for adult HLT have been expanded to include congenital heart disease and idiopathic pulmonary artery hypertension [2] . HLT recipients have survival rates of 63% at one year, 52% at three years, and 45% at five years [2] .
In Korea, a total of 17 HLTs have been performed be- 
2) Donor selection, organ procurement, and transplant technique
We have paid special attention to manage the donor organs properly from the donor selection stage. Techniques used to assess organ quality included chest radiography, arterial blood gas determination, bronchoscopy, echocardiography, and visual inspection of the heart and lungs [3, 4] . We tried to perform flexible bronchoscopy in every case to evaluate the airways and to remove retained secretion.
The donor and recipient operations were performed using previously described techniques [5] . Following sternotomy, we opened mediastinal pleura of both side and carefully examined the condition of donor's lung. If there was atelectasis, we requested to adjust the ventilation setting to expand the lungs fully. After dissection of the trachea, the superior vena cava (SVC), inferior vena cava (IVC), ascending aorta, and main pulmonary artery, cannulae were placed in order to provide preservative solutions to heart and lung. Before aorta cross-clamping, 25,000 units of heparin were administered intravenously and prostaglandin E1 (500 μg) was administered into the main pulmonary artery. When the systolic blood pressure dropped to under 90 mmHg following the administration of prostaglandin E1, aortic cross-clamping was carried out and cardioplegic infusion was started. The left atrial appendage was amputated in order to ensure complete emptying of the heart. The heart was preserved using 2 L of histidine-tryptophan-ketoglutarate solution (Custodiol HTK; Essential Pharmaceuticals, Newtown, PA, USA) infused through the aortic root cannula. The lungs were preserved using antegrade pulmoplegia with 5 L of low-potassium dextran solution (Perfadex; Vitrolife AB, Kungsbacka, Sweden) through the main pulmonary artery, with venting through the IVC and LA auricle. If the cold ischemic time was predicted to be more than 120 minutes, 1 L of Perfadex solution was infused again into the lung allograft at recipient's operation room before anastomosis. At the time of tracheal stapling, the lungs were inflated enough to prevent atelectasis. Cold HTK solution was used for graft storage during returning to recipient's operation room.
Standard median sternotomy was performed in eight recipients, while two patients underwent the clamshell approach due to severe adhesion. We used standard cardiopulmonary bypass (CPB) strategy including aortic and bicaval cannulations, and tried to cannulate the aorta, the SVC, and the IVC as distally as possible. After the initiation of CPB and cooling using ice slush, recipient cardiectomy and bilateral pneumonectomies were completed immediately after the arrival of the donor heart-lung bloc. The tracheal anastomosis was done first using a running polydioxanone 4-0 suture (PDS II;
Johnson & Johnson K.K., Seoul, Korea) on the posterior side, and intermittent suturing was later performed on the anterior side using the same suture material. Next, the aortic anastomosis was performed. After the cross-clamp was removed using standard de-airing maneuvers, 500 mg of methylprednisolone was administered intravenously. Anastomosis of the SVC was performed, followed by anastomosis of the Postoperative immunosuppression consisted of a triple-maintenance therapy based on steroids, mycophenolate mofetil, and a calcineurin inhibitor. Among the calcineurin inhibitors, tacrolimus (FK506) was used first and cyclosporine (CsA) was used as a second choice when complications related to tacrolimus occurred. Tacrolimus was begun on the second postoperative day at a dose of 0.05-0.1 mg/kg for 24 hours, and the target continuing level was 10-15 ng/mL for six months and 8-12 ng/mL after three days. If CsA was used rather than tacrolimus, it was usually administered on the second postoperative day at an initial dose of 2-3 mg/kg or half the dose as a four-hour infusion twice a day, and was continued until the patient was able to take oral medication.
A 500-mg dose of methylprednisolone was given intraoperatively after weaning of CPB. Two additional postoperative doses were given (1 mg/kg every 12 hours for 24 hours) until the day after the operation, and a half dose was then given for two weeks, based on the assumption that this would decrease the incidence of bronchial anastomotic complications. After two weeks, steroids were changed to oral prednisone with a daily dosage of 0.6 mg/kg, tapering to 0.2 mg/kg/day at six weeks and 0.1 mg/kg/day at six months.
All patients were required to undergo follow-up at our transplant outpatient clinic, which is associated with the department of pulmonology and critical care medicine. Peak expiratory flow was calculated daily in all patients using a portable peak flow meter to detect acute rejection or early lung injury. Routine spirometry was performed during the first six months after transplantation. Thereafter, bronchoscopies were only performed for special indications such as infection or rejection. Acute rejection was diagnosed by chest computed tomography and bronchoscopy if pulmonary function decreased. Chronic rejection, including restrictive allograft syndrome or bronchiolitis obliterans syndrome (BOS), was also made using concurrent forced vital capacity and forced expiratory volume in one second [6] .
4) Surveillance and treatment of rejection
The patients did not undergo surveillance endomyocardial biopsies, but did have a routine transthoracic echocardiogram once a week until discharge and two, four, six, and 12 months after discharge.
The surveillance bronchoscopy was routinely performed at two, four, six, and 12 months and annually thereafter. Either endomyocardial or lung biopsies were obtained only when rejection was suggested clinically. Patients were followed up at the out-patient clinic of the department of pulmonology and critical care medicine. In cases of the patients showed signs of moderate or severe rejection, intravenous methylpredni- 
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solone (1 g/day for three days) was injected, followed by a two-week tapering course of prednisone. Persistent rejection was treated with an additional course of steroids followed by everolimus and low-dose cyclosporine.
5) Statistical analysis
Statistical analysis was performed using IBM SPSS software ver. 22.0 (IBM Co., Armonk, NY, USA). Data are shown as the mean plus or minus the standard error of the mean. The overall survival included all deaths from any cause during the follow-up period, whereas live patients were right-censored at the last available follow-up.
RESULTS

1) Patient demographics
Between July 2010 and August 2014, a total of 11 patients underwent HLT in our medical institution, one of whom was excluded due to undergoing simultaneous heart, lung, and liver transplantation. Table 1 
2) Organ donor and transplant operations
Five patients were female and five were male. The mean donor age was 29.1±13.7 years (range, 11 to 52 years) ( Table 2) .
Clinical Outcomes of Heart-Lung Transplantation: Single-Center Experience 
3) Morbidity and mortality
The morbidity and mortality data are presented in Table 3 . and septic shock (n=1). The survival duration of these patients was 22, 28, and 42 months, respectively. The actuarial survival rates at one, two, and three years after HLT were 80%, 67%, and 53%, respectively (Fig. 1) . The common late complications were BOS in two patients (25%), chronic renal failure in two patients (25%), and hematogenous infection in two patients (25%). All survivors were in New York Heart Association class I or II after discharge.
DISCUSSION
In this study we presents the clinical outcomes of HLTs performed at the Asan Medical Center over a five-year period, with acceptable short-and mid-term survival rates. The survival rates at one year and three years in this study were 80% and 53%, whereas they were 63% and 52% in the (ISHLT) study [2] . According to the ISHLT study, the most common causes of death during the first 30 days after heart-lung transplantation were graft failure, technical complications, and non-cytomegalovirus infections. In late period, BOS/late graft failure (lung or heart) and non-cytomegalovirus infections were the common causes of death [2] . Due to the low number of cases, we were unable to analyze the cause of early and late deaths in order to determine statistically significant trends in the cause of death. However, the leading causes of early and late mortality were septic shock and BOS.
During the last 34 years, HLT has provided hope to a large number of patients and a great benefit to many.
According to the International Society for Heart and Lung
Transplantation study [2] , the major indications for HLT are congenital heart disease (35.5%), idiopathic primary pulmonary hypertension (27.4%), cystic fibrosis (13.9%), and acquired heart disease (5.4%). The decision to list patients with idiopathic primary pulmonary hypertension for HLT rather than for bilateral lung transplantation was made depending on the right heart function and its predicted recovery after isolated lung transplantation [7] . However, until recently it has been difficult to assess the reversibility of right ventricular function in patients with right heart failure due to the lack of definite criteria. Consequently, the decision to perform HLT was made by experienced cardiologists who had specialized in performing heart transplantation for 20 years in consultation with pulmonologists based on the echocardiogram, cardiac computed tomography, and/or information derived from cardiac catheterization. According to the Asan Medical
Center protocol, six patients with end-stage lung disease underwent HLT rather than isolated lung transplantation due to moderate-to-severe right heart failure with pulmonary HTN, although the ejection fraction was sometimes within the normal range. Three patients had heart failure (congenital or acquired) and their pulmonary function was irreversibly aggravated.
Chronic allograft rejection after lung transplantation is manifested by 'constrictive' BOS and is physiologically characterized by progressive expiratory airflow obstruction seen on pulmonary function testing [7] . With regard to HLT, the lung grafts seem to protect the heart such that pulmonary infiltration usually precedes or prevents myocardial infiltration [8] .
Meanwhile, as the heart does not provide immunoprotective effects for the lungs, HLT recipients exhibit BOS at a rate similar to lung transplantation recipients [9] . Therefore, BOS is a major factor limiting long-term survival after HLT as well as lung transplantation, affecting approximately one third of all patients within three years and half of all patients within five years [10] . In the past, BOS was considered an irreversible and incurable condition, whereas azithromycin can now improve airflow limitation in a significant proportion of patients with even long-standing BOS [11] . Tacrolimus conversion from CsA [12] or extracorporeal photopheresis [13] has also shown to be an effective adjunctive treatment. However, in our study, we could not confirm significant difference of survival outcomes of the patients who required ECMO support (n=6) and MV (n=8) before HLT when compared to unsupported group. This finding might be due to the small number of patients. Early mortality occurred preoperatively in 17% (1/6) of the ECMO-supported patients and in 25% (1/4) of the unsupported patients. The survival rate of the ECMO-supported patients was 83% over the course of one to three years, whereas the survival rate of the unsupported patients was 75% at one year and 25% at three year, although this was not a statistically significant difference (p=0.495). The MV-supported patients had longer preoperative ICU stays than the unsupported patients (45 days vs. eight days), although this difference did not reach statistical significance (p=0.248). It is likely that these patients are susceptible to the same factors that cause worse outcomes in mechanically ventilated HLT patients, such as airway colonization and the risk of post-transplantation pneumonia [17] .
Patients requiring MV are also often deconditioned [18, 19] , which can also delay their recovery from transplant surgery.
The main limitation of this study is that the number of the patients is small. However our study does provide valuable, recent, and detailed morbidity and mortality information regarding post-HLT patients in a Korean cohort. A cumulative analysis of HLT cases and a multicenter study will be required in order to further evaluate the actual survival outcomes and prognosis after HLT in Korean patients.
In conclusion, HLT is a procedure that is infrequently performed even in medical centers with large heart and lung transplant programs. It is critical that recipients be carefully chosen and that all aspects of the transplant procedure be meticulously planned in advance. These challenging procedures require experienced heart and lung surgeons with expertise in HLT in order to ensure the optimal utilization of these precious organs. Major advances in infection prophylaxis and treatment as well as continuously improved immunosuppressive regimens, together with our increasing clinical experience, allow us to expect a higher rate of mid-and long-term survivors in the future.
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